GCC Veterinary Medicine Market (2026 - 2033)

GCC Veterinary Medicine Market Summary

The GCC veterinary medicine market size was valued at USD 861.7 million in 2025 and is projected to grow USD 946 million in 2026 to USD 1,900.4 million by 2033, at a CAGR of 10.5% from 2026 to 2033. The market is driven by rising demand for meat, poultry and dairy products, alongside government food-security initiatives that support livestock productivity and animal health management. The need to prevent and control livestock diseases and zoonotic infections is increasing demand for vaccines, anti-infectives, antiparasitics, and other preventive treatments.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

The GCC veterinary medicine market is characterized by uneven demand across countries, a strong livestock-oriented customer base, and substantial cross-border dependence on imported products. Saudi Arabia is the largest market for veterinary vaccines by trade value: it accounted for vdvrh 74% of GCC veterinary vaccine imports in 2024, worth USD 124 million, while the UAE zeesvvhzt bvv efrcf 13% (USD 23 million) and Oman 5.5%. However, import volumes show a more varied pattern: Saudi Arabia imported approximately 872 tons of veterinary vaccines in 2024, compared with 165 tons in the UAE, 86 tons in Qatar and 81 tons in Oman. This indicates that market activity is concentrated in the two largest economies, while smaller markets such as Qatar are also relevant to regional demand.

The market also reflects differences in product mix, pricing, and supply-chain structure between GCC countries. In 2024, the average import price of veterinary vaccines was approximately USD 135,581 per ton, but prices varied considerably by destination: Kuwait recorded around USD 175,925 per ton, compared with approximately USD 60,078 per ton in Qatar. This variation may reflect differences in vaccine portfolios, product specifications and shipment composition rather than simply differences in retail prices. The UAE and Kuwait also have some domestic vaccine production capacity, although regional supply remains reliant on imports. Overall, competition is shaped by the ability of manufacturers and distributors to maintain product registrations, reliable cold-chain logistics and access to veterinary clinics, farms and government procurement channels.

Market Concentration & Characteristics

The industry is characterized by international supplier participation, country-level product approvals and specialized distribution requirements. Veterinary medicines are subject to regulatory controls covering product registration, manufacturing standards, labeling, importation, and legal supply status. Saudi Arabia’s SFDA, for instance, has specific guidance governing the classification and supply status of veterinary medicinal products, alongside the GCC Veterinary Products Act and Regulation. Distribution typically involves manufacturers, authorized importers, veterinary pharmacies, clinics, livestock suppliers, and government procurement channels. Biologics and vaccines require additional attention to storage conditions and cold-chain handling, while medicines for food-producing animals must be managed in accordance with relevant use and residue requirements.

Competition is shaped less by price alone and more by product registration, local distribution reach, technical support and the ability to supply different animal-health segments. Multinationals typically leverage established brands, research capabilities and specialised products, while regional manufacturers can compete through proximity, product availability and established distributor relationships. Market participation also varies by business model: some companies focus on manufacturing and importing medicines, while others provide diagnostics, veterinary services or distribution.

To learn more about this report, Download Free Sample Report

Innovation in the GCC veterinary medicine industry is increasingly focused on preventive vaccines, advanced biologics, disease surveillance and diagnostic technologies, rather than only conventional treatments. For instance, in June 2026, Saudi Arabia’s signed a partnership agreement with the National Livestock and Fisheries Development Program; AniVax and Boehringer Ingelheim include plans for a national antigen bank covering local and regional disease strains, vaccine research, field trials, and improved diagnostic capabilities. The collaboration also includes technical training and epidemiological data exchange, indicating a shift towards locally adapted disease-prevention solutions.

Publicly disclosed evidence of large-scale mergers and acquisitions specifically involving veterinary medicine companies in the GCC is limited. The market appears to rely more on strategic partnerships, distribution agreements, technology transfers, and localization collaborations than on major acquisitions. For Instance, Saudi Arabia’s agreements with Ceva and Boehringer Ingelheim demonstrate how international animal-health companies are entering or strengthening their regional presence through cooperation with government-linked programs and local partners. These arrangements allow companies to access local manufacturing opportunities and distribution networks without necessarily acquiring existing businesses.

Regulation have a direct impact on product registration, market entry, manufacturing, importation, and distribution across the GCC. The GCC Veterinary Products Law establishes a common regional framework for veterinary products and manufacturing standards, including good manufacturing practices; however, implementation and licensing remain the responsibility of each country’s competent authority. The UAE strengthened its framework through a Federal Decree-Law issued on 10 December 2025, covering product development, registration, pricing, import, export, distribution and sale. It also introduced a fast-track marketing authorization route for qualifying innovative veterinary products. These requirements increase compliance obligations but provide clearer pathways for manufacturers that meet quality and safety standards.

Companies are broadening veterinary portfolios beyond conventional medicines towards vaccines, biologics and products targeting region-specific animal diseases. Saudi Arabia’s February 2026 MoU with France’s Ceva includes cooperation on poultry vaccines, mRNA technology, camel MERS vaccine research, and rabies solutions. Separately, the June 2026 agreement involving Boehringer Ingelheim and AniVax covers priority vaccine development, an antigen bank and diagnostic capabilities. These initiatives illustrate opportunities to expand product ranges across poultry, livestock and camel health, while adapting formulations and disease coverage to regional requirements.

Saudi Arabia is positioning itself as a potential regional base for veterinary biotechnology manufacturing and distribution. The Veterinary Biotech Park in Dhurma, launched in December 2025, is designed to attract international companies involved in vaccine and veterinary-product development, provide laboratory infrastructure, and support regional headquarters. Its stated target markets extend beyond Saudi Arabia to the GCC, the wider Middle East and Africa. This creates opportunities for manufacturers to establish production or research operations in Saudi Arabia and serve neighboring markets through regional distribution networks, subject to each destination country’s product registration and import requirements.

Analyst Perspective

The GCC veterinary medicine market is expected to experience steady development, supported by sustained demand for animal health products across commercial livestock, poultry and companion animals. Demand is expected to remain particularly strong in production-animal healthcare, as governments and industry participant’s priorities livestock productivity, disease prevention, food security and compliance with animal-health standards. At the same time, growing pet ownership and increasing access to veterinary services are broadening demand for preventive and therapeutic treatments for companion animals. 

Animal Insights

On the basis of animals, production animals held the largest share of 63.0% in 2025, driven by the region’s substantial livestock and commercial poultry sectors. According to the GCC Annual Statistical Yearbook, the region had approximately 42.5 million livestock in 2024, comprising 25.7 million sheep (60.5% of the total), 12.5 million goats, 3.2 million camels and 1.2 million cattle. This large production-animal population creates recurring demand for vaccines, antibiotics, antiparasitic treatments, nutritional medicines and disease-prevention products. Commercial poultry production further strengthens this demand. According to the report published by the Statistical Center for the Cooperation Council, Saudi Arabia alone produced approximately 1.3 million tons of broiler chicken in 2024, an increase of 12.9% from 2023. The scale of livestock and poultry farming, together with the need to maintain animal health, productivity, and food supply, supports the dominant contribution of production animals to veterinary medicine sales.

The companion animal segment in the GCC veterinary medicine market is the fastest growing, with a CAGR of 10.9% over the forecast period. This growth is supported by increasing pet ownership, changing attitudes towards cats and dogs, rising disposable incomes and increase in spending on preventive and specialized veterinary care. For instance, the UAE pet population increased by 59%, from approximately 588,700 in 2014 to 938,000 in 2024, according to a 2025 USDA Foreign Agricultural Service report. This expanding pet base is creating recurring demand for vaccinations, anti-parasitic medicines, antibiotics and treatments for chronic conditions. Rising expenditure on preventive healthcare and access to specialized veterinary clinics are further supporting demand for higher-value medicines and advanced treatments.

Product Insights

On the basis of product, pharmaceuticals held largest share of 58.5% in 2025 due to their extensive use in the treatment and management of animal diseases across livestock, poultry and companion animals. Veterinary pharmaceuticals, including antibiotics, antiparasitics, anti-inflammatory drugs and other therapeutic medicines, are used to manage bacterial and parasitic infections, respiratory disorders, digestive diseases and other common animal-health conditions. Their demand is supported by the need for timely treatment, routine veterinary care and maintaining animal productivity in commercial farming operations. Furthermore, the availability of medicines for both acute and chronic conditions creates a broad and recurring demand base across the region. For instance, in February 2026, UAE's Emirates Drug Establishment (EDE) is officially launched. It provides an instance of growing institutional support for pharmaceutical manufacturing and supply-chain development. Its Holistic National Manufacturing Project explicitly includes the localization of veterinary products alongside human medicines and agricultural inputs.

The biologics segment is anticipated to grow at the fastest CAGR of 10.7% over the forecast period of 2026-2033, driven by increasing demand for preventive healthcare, vaccination and advanced disease-control solutions for livestock and poultry. Veterinary biologics, particularly vaccines, help prevent infectious diseases, reduce animal mortality and minimize production losses, making them important for livestock productivity and regional food security. The need for effective control of zoonotic diseases further strengthens demand; according to Saudi Arabia’s National Livestock and Fisheries Development Program, approximately 75% of animal diseases are transmissible to humans, highlighting the importance of veterinary disease prevention and surveillance.

Saudi Arabia is supporting this trend through initiatives to develop domestic veterinary biologics capabilities. For instance, in December 2025, the country launched the Veterinary Biotech Park in Dhurma, comprising laboratory, research and integrated industrial facilities to attract international companies involved in vaccine and veterinary-product development. The initiative also includes opportunities to localize foot-and-mouth disease vaccine production and aims to serve Saudi Arabia, the GCC, the wider Middle East and Africa. By encouraging research, technology transfer and local manufacturing, these developments are expected to improve access to veterinary vaccines and advanced biologics, supporting the segment's projected growth across the region.

Route of Administration Insights

Based on route of administration, injectable dominated the market with share of 44.4% in 2025, since they provide rapid and reliable drug delivery, accurate dosing and effective administration of vaccines, antibiotics, antiparasitics and other therapeutic products. Injectable formulations are widely used in livestock and poultry healthcare, particularly for vaccination programs, disease treatment and herd-level disease prevention. They are also suitable for administering medicines to animals that may be difficult to treat orally, ensuring that the required dose is delivered directly into the body. In commercial livestock operations, injectable vaccines and medicines are particularly important for managing infectious diseases and reducing treatment-related losses. The expansion of veterinary vaccine development and localization initiatives in Saudi Arabia, including research into foot-and-mouth disease vaccines, further illustrates the continued relevance of injectable products in regional animal healthcare.

Moreover, others segment in the GCC veterinary medicine market is expected to grow at a fastest CAGR. Growth is likely to be supported by increasing adoption of specialized drug-delivery methods, including intranasal, intraocular, intrauterine and intramammary administration, depending on the medicine and animal species. These routes enable targeted treatment of specific conditions, such as respiratory infections, eye disorders, uterine infections and mastitis in dairy animals. Intranasal vaccines and medicines offer a non-invasive approach to respiratory disease prevention, while intramammary formulations are used to treat udder infections in dairy cattle. The growing focus on specialized veterinary care and disease-specific treatment is expected to encourage demand for these alternative administration routes across livestock, poultry and companion animals. Their use can provide targeted drug delivery and, in certain applications, reduce the need for systemic medication.

Distribution Channel Insights

Veterinary hospitals & clinics segment dominated with a share of 39.1% in 2025, owing to their role as primary points of diagnosis, prescription and treatment for both livestock and companion animals. These facilities provide access to qualified veterinarians who select and administer prescription medicines, vaccines, antibiotics, antiparasitics and specialized treatments based on animal health requirements. The growing number of companion animal clinics, particularly in urban centers such as Dubai, Abu Dhabi and Riyadh, is also supporting medicine sales through this channel. In addition, veterinary hospitals provide diagnostic services, surgical care and preventive healthcare, generating demand for a wider range of medicines than channels focused mainly on product retail.

To learn more about this report, Download Free Sample Report

E-commerce segment is expected to grow with highest CAGR of 11.6% over the forecast, driven by increasing internet penetration, widespread smartphone usage and the growing adoption of digital purchasing platforms across the region. Online channels offer veterinary clinics, livestock owners and pet owners convenient access to medicines, vaccines, nutritional products and parasite-control treatments, along with product comparisons, home delivery and easier repeat ordering. The expansion of pet ownership and demand for routine treatments, particularly flea and tick medications, supplements and other regularly purchased products, is further encouraging online purchases.

Additionally, the development of specialized online pet-care platforms and digital pharmacy services in countries such as the UAE and Saudi Arabia is improving access to veterinary products. E-commerce platforms can also serve customers in locations with limited access to physical veterinary pharmacies, although prescription requirements, product authenticity, cold-chain logistics and country-specific import regulations remain important considerations. The convenience of digital ordering and the expansion of online veterinary retail are therefore expected to support faster growth in this channel compared with traditional distribution channels.

Regional Insights

Saudi Arabia held the largest share, driven by rising companion-animal healthcare demand, and government efforts to strengthen domestic production, improving animal disease control, and enhancing regulatory capabilities. For instance, in December 2025, Veterinary Biotech Park in Dhurma is launched to attract international companies, localize veterinary vaccine and product development, and strengthen supply-chain resilience. Additionally, in April 2025, MoU between the Saudi Food and Drug Authority (SFDA) and France’s ANSES is expected to support scientific collaboration, technical training, and improvements in veterinary medicine quality, safety, efficacy, and regulatory evaluation. Together, these initiatives could encourage investment, expand local production capacity, and improve access to veterinary medicines, supporting the countries livestock productivity and food-security objectives.

UAE veterinary medicine market held the second-largest share in 2025 driven by rising pet ownership, demand for advanced companion-animal care, livestock health management and national food-security priorities. Demand spans companion-animal medicines, such as vaccines, antiparasitics and treatments for skin or joint conditions and production-animal products, including poultry vaccines, antibiotics and livestock parasite-control medicines. For instance, in June 2026, UAE-based Al Khayyat Investments announced a USD 100 million investment in VetHealth, covering pharmaceuticals, biologicals, biosecurity, nutrition and diagnostics. Additionally, growing regulatory development is contributing to market growth. For instance, UAE’s Federal Decree-Law No. 21 of 2025, effective from 1 January 2026, strengthens the framework for veterinary product registration, manufacturing, importation and distribution, creating a more structured environment for suppliers and manufacturers.

Key GCC Veterinary Medicine Company Insights

The GCC veterinary medicine market is competitive, with multinational animal health companies competing alongside regional vaccine manufacturers and suppliers. Key players include Zoetis, Merck Animal Health (MSD), Boehringer Ingelheim, Elanco, Ceva Santé Animale, Virbac, Dechra Pharmaceuticals, Vetoquinol, Phibro Animal Health, MEVAC and JOVAC. Their portfolios span veterinary pharmaceuticals, vaccines, parasiticides and other animal health products for livestock, poultry, camels and companion animals. MEVAC and JOVAC are notable regional players in veterinary vaccines. Competition is driven by product efficacy and safety, portfolio breadth, pricing, regulatory approvals, veterinary relationships and distribution capabilities. Multinational companies benefit from established brands and broad product portfolios, while regional manufacturers can compete in selected vaccine categories and local supply opportunities. Demand for livestock disease control, food security and companion animal care is also encouraging investment in local manufacturing and partnerships.

Key GCC Veterinary Medicine Companies

The following key companies have been profiled for this study on the GCC veterinary medicine market.

• Zoetis

• Merck & Co., Inc.

• Ceva

• Boehringer Ingelheim International GmbH

• Elanco

• Virbac

• Dechra Pharmaceuticals

• Vetoquinol 

• Phibro Animal Health Corporation

• MEVAC

• JOVAC 

Recent Developments

• In February 2026, CEVA partnered with Saudi Arabia to localize veterinary vaccine manufacturing, transfer advanced technology, and develop vaccines targeting poultry diseases, rabies, and MERS-CoV in camels. The initiative aims to strengthen domestic production, biosecurity, and food security through an initial investment of approximately USD 66 million and participation in the Dhurma Biotech Park.

• In June 2026, Boehringer Ingelheim, AniVax, and National Livestock and Fisheries Development Program signed a tripartite MoU with Saudi Arabia to promote local veterinary vaccine manufacturing, establish a national antigen bank, and strengthen research and development. The partnership also aims to build local expertise, improve disease surveillance, and enhance the Kingdom’s veterinary vaccine supply security in line with Saudi Vision 2030.

• In April 2025, Ceva Animal Health participated in the Middle East Poultry Expo 2025 in Saudi Arabia, which attracted over 320 exhibitors from 40 countries and more than 11,000 visitors from 54 nations. The company used the event to strengthen regional partnerships and promote poultry-health solutions, working alongside its local distributor, MAS, to support poultry productivity and food security.

GCC Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the GCC veterinary medicine market report based on product, animal, route of administration, distribution channel, and country:

• GCC Veterinary Medicine Market by Product Outlook (Revenue, USD Million 2021 - 2033)

  • Biologics

    • Vaccines

      • Modified/ Attenuated Live

      • Inactivated (Killed)

      • Other Vaccines

    • Other Biologics

  • Pharmaceuticals

    • Parasiticides

    • Anti-infectives

    • Anti-inflammatory

    • Analgesics

    • Others

  • Medicated Feed Additives

• GCC Veterinary Medicine Market by Animal Outlook (Revenue, USD Million 2021 - 2033)

  • Production Animals

    • Poultry

    • Swine

    • Cattles

    • Sheep & Goats

    • Others

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others

• GCC Veterinary Medicine Market by Route of Administration Outlook (Revenue, USD Million 2021 - 2033)

  • Oral

  • Injectable

  • Topical

  • Others

• GCC Veterinary Medicine Market by Distribution Channel Outlook (Revenue, USD Million 2021 - 2033)

  • Veterinary Hospitals & Clinics

  • E-commerce

  • Offline Retail Stores

  • Others

• GCC Veterinary Medicine Market Country Outlook (Revenue, USD Million 2021 - 2033)

  • Saudi Arabia

  • Oman

  • UAE

  • Kuwait

  • Qatar

  • Bahrain

Research Methodology

The GCC veterinary medicine market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each GCC veterinary medicine segment quantified using the revenue-capture definitions in the table below.

Estimation Model

To learn more about this report, Download Free Sample Report

Delivered Customizations

This report has been delivered with the following In-depth customizations